Sun Pharmaceuticals Inc.

San Diego, CA, United States

Sun Pharmaceuticals Inc.

San Diego, CA, United States
SEARCH FILTERS
Time filter
Source Type

News Article | July 24, 2017
Site: www.prnewswire.com

The Eye-D latanoprost insert is designed to provide sustained IOP-lowering for patients who have difficulty taking their prescribed eye drops for the treatment of glaucoma on a continuous daily basis. BioLight's first-in-human study, this randomized, controlled, exploratory Phase 1/2a clinical trial was designed to compare three doses of its Eye-D latanoprost inserts to once-daily latanoprost eye drops. Following a simple, in-office procedure, the sustained release Eye-D latanoprost inserts were tested for 12 weeks and compared to once-daily latanoprost eye drops for the same period. The Phase 1/2a results comprise data from 77 glaucoma patients that were collected from 19 clinical centers across the United States. The data demonstrated that a single placement of the Eye-D latanoprost insert of one of the three doses provided the best sustained reduction in IOP throughout the 12 weeks follow up, with a positive safety profile. "Ophthalmologists today continue to struggle with finding effective solutions to the significant problem of non-adherence to the pharmaceutical treatment of patients with glaucoma," said Dr. Howard Barnebey, MD, who served as a Principle Investigator in the study. "Non-adherence is a complex problem to solve.  Several therapeutic approaches that aimed to address the lack of therapy compliance and persistence have either failed or are still in development." Dr. Barnebey continued, "The Eye-D latanoprost insert has now successfully demonstrated effective intra-ocular pressure lowering for three months after subconjunctival placement of the insert in human eyes, and was well tolerated.  This innovative insert presents a promising approach to improving therapeutic compliance, bypassing the issues of patients remembering to take medication as well as instilling it in their eyes. I am excited to participate in further development of Eye-D latanoprost insert." Suzana Nahum Zilberberg, BioLight's CEO, commented, "We are very happy with the success of this clinical trial which demonstrated that the Eye-D latanoprost insert is safe and efficacious, and intend to continue our discussions with potential strategic partners, aiming to advance the development and approval process for the Eye-D latanoprost insert, while, at the same time, promoting additional steps that will assist in optimizing the treatment for glaucoma patients. This novel technology and its first indication, have the potential of becoming an important advance in the treatment of glaucoma patients". BioLight addresses a number of significant unmet medical needs with a pipeline of ophthalmic products and product candidates, which are in various commercial and clinical stages, including: IOPtiMate™, a laser-based non-invasive surgical treatment for glaucoma; TeaRx™, a diagnostic solution that provides a multi-assay analysis of tear film constituents in order to identify one or more underlying causes of dry eye syndrome, or DES; Eye-D, an in-office insertable platform that provides for controlled release of ophthalmic medications over time; OphRx's lyotropic liquid crystals, or LLC, a non-invasive drug delivery technology administered through eye drops as an alternative to current ocular delivery modalities; and  LIPITEAR™, a microemulsion consisting of Phospholipidis and Triglycerides, which forms a tear-like elastic lipid shield which is indicated for use in DES, post-operative ocular surgery (e.g. refractive surgery, cataract surgery and corneal transplant) and corneal erosions.  BioLight has also invested, through Micromedic, in innovations in cancer diagnostics. Leading key investors are Mr. Israel Makov, Chairman of Sun Pharmaceuticals, former CEO and President of Teva Pharmaceuticals and former Chairman of Given Imaging, Mr. Dilip Shanghvi, founder of Sun Pharmaceuticals, India's largest pharmaceutical company, Mr. Dan Oren, founder and CEO of Dexcel Pharma, the second-largest pharmaceutical manufacturer in Israel and Rock-One, a Hong Kong-based investment company. For more information please visit the Company's website at http://www.bio-light.co.il


"In developed countries, discretionary research funding for cancer is on a rise. Increased investments towards development of better treatment against malignant mesothelioma is observed globally". In 2017, the global malignant mesothelioma market is expected to reach a value of US$ 338 Mn. The report observes that increasing use of asbestos for commercial purposes is fuelling the incidence of malignant mesothelioma among people. By the end of 2025, the global market for malignant mesothelioma is anticipated to have soared at 7.5% CAGR, reaching an estimated US$ 604 Mn in value. Studies focused on cause of malignant mesothelioma are being publicized to boost awareness. Through such work, people are becoming more aware, particularly with respect to association of the HOXB4 gene is stopping the maturation of mesothelioma tumor. Overall, the global market for malignant mesothelioma is also witnessing an increased adoption of combination therapies. Many companies are promoting the cumulative use of chemotherapy and immune-oncology procedures in treatment of malignant mesothelioma. In addition to this, malignant mesothelioma is gaining incidence among men. Exposure to asbestos is likely to remain concentrated to male demographics of the world. Increased exposure to such toxic elements is aggravating the incidence of mesothelioma in men. Key players in the global malignant mesothelioma market are also collaborating with leading research organizations to develop combination drugs on mesothelioma, the approval of which is drawing highest regard of authorities such as the FDA. The report has profiled leading players in the global malignant mesothelioma market, and they include Sanofi, Eli Lilly and Company, Teva Pharmaceuticals, Boehringer Ingelheim GmbH, Mylan N.V., Fresenius Kabi AG, Sun Pharmaceuticals Industries Ltd., Corden Pharma International GmbH, Concordia International Corp., Kyowa Hakko Kirin Co Ltd., Polaris Pharmaceuticals, Inc., MolMed SpA, Ono Pharmaceutical Co. Ltd., Nichi-Iko Pharmaceutical Co., Ltd., AstraZeneca Plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, and Pfizer Inc. A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/10628 Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance. To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.


"In developed countries, discretionary research funding for cancer is on a rise. Increased investments towards development of better treatment against malignant mesothelioma is observed globally". In 2017, the global malignant mesothelioma market is expected to reach a value of US$ 338 Mn. The report observes that increasing use of asbestos for commercial purposes is fuelling the incidence of malignant mesothelioma among people. By the end of 2025, the global market for malignant mesothelioma is anticipated to have soared at 7.5% CAGR, reaching an estimated US$ 604 Mn in value. Studies focused on cause of malignant mesothelioma are being publicized to boost awareness. Through such work, people are becoming more aware, particularly with respect to association of the HOXB4 gene is stopping the maturation of mesothelioma tumor. Overall, the global market for malignant mesothelioma is also witnessing an increased adoption of combination therapies. Many companies are promoting the cumulative use of chemotherapy and immune-oncology procedures in treatment of malignant mesothelioma. In addition to this, malignant mesothelioma is gaining incidence among men. Exposure to asbestos is likely to remain concentrated to male demographics of the world. Increased exposure to such toxic elements is aggravating the incidence of mesothelioma in men. Key players in the global malignant mesothelioma market are also collaborating with leading research organizations to develop combination drugs on mesothelioma, the approval of which is drawing highest regard of authorities such as the FDA. The report has profiled leading players in the global malignant mesothelioma market, and they include Sanofi, Eli Lilly and Company, Teva Pharmaceuticals, Boehringer Ingelheim GmbH, Mylan N.V., Fresenius Kabi AG, Sun Pharmaceuticals Industries Ltd., Corden Pharma International GmbH, Concordia International Corp., Kyowa Hakko Kirin Co Ltd., Polaris Pharmaceuticals, Inc., MolMed SpA, Ono Pharmaceutical Co. Ltd., Nichi-Iko Pharmaceutical Co., Ltd., AstraZeneca Plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, and Pfizer Inc. A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/10628 Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance. To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.


News Article | July 21, 2017
Site: www.reuters.com

A Novartis logo is pictured on its headquarters building in Mumbai April 1, 2013. ZURICH (Reuters) - A European Medicines Agency (EMA) panel recommended on Friday approval of a new Novartis drug to be used against a tough-to-cure form of blood cancer as the Swiss drugmaker makes headway on refreshing its oncology portfolio. The EMA's Committee for Medicinal Products for Human Use (CHMP) backed Rydapt against acute myeloid leukaemia (AML) in newly diagnosed patients and three other indications. Rydapt was also recommended as a treatment for adults with advanced systemic mastocytosis, a rare disease in which the body's mast cells accumulate rapidly. This latest CHMP opinion sets the stage for likely European Commission approval this year. Rydapt, whose U.S. wholesale cost is nearly $7,500 for a two-week supply, was approved by the U.S. Food and Drug Administration in April. Novartis is rebuilding its portfolio of cancer drugs after the expiration of patents on its blockbuster Gleevec in early 2016 exposed the $5 billion-a-year seller to generics from rivals including Sun Pharmaceuticals. AML is a rare and aggressive cancer of the blood and bone marrow. Other recent Novartis approvals or regulator recommendations have included Kisqali against a tough-to-treat form of breast cancer. The company is also aiming for the FDA's blessing for its first-of-its-kind cell therapy CTL019 this year. Novartis is banking on these cancer medications as well as heart failure drug Entresto, psoriasis treatment Cosentyx and its Sandoz unit's growing portfolio of biosimilars to help return it to sales growth starting in 2018.


MIDLAND, Mich.--(BUSINESS WIRE)--Andrew Liveris, chairman and chief executive officer of The Dow Chemical Company (NYSE: DOW), was presented today with the 2017 Global Leadership Award from the U.S.-India Business Council (USIBC). The award was presented to Liveris and Adi Godrej, chairman of the Godrej Group, by John Chambers, USIBC chairman and executive chairman of Cisco, during USIBC’s 42nd Annual Leadership Summit in Washington, D.C. – a prestigious event gathering senior business executives and high-ranking political officials, including Vice President Mike Pence. The award recognizes honorees for creating inclusive business environments, integrating India in the global supply chain and advancing core values such as manufacturing, innovation and scale in tough market conditions. “ On behalf of Dow employees around the world who work every day to strengthen the U.S.-India partnership to create mutually-beneficial, sustainable value, I am honored to accept this award,” said Liveris. “ Advanced manufacturing technologies from Dow and other partners have a pivotal role to play as Prime Minister Modi continues to transform the dynamic Indian economy, including economic diversification, sustainable growth and innovation.” This event aligned with Prime Minister Modi’s first meeting with President Donald Trump in Washington, D.C. to discuss bilateral partnership and common goals of promoting cooperation on trade and economic partnership. Liveris’ recognition reflects his leadership on core U.S.-India political goals, including mutual interest in promoting more value-add domestic manufacturing. Through President Trump's Manufacturing Jobs Initiative, Liveris is working to help identify new ways to spur innovation, revitalize the U.S. manufacturing sector, and drive economic growth and prosperity. To this end, he has led Dow to collaborate with governments on Advanced Manufacturing Plans, including co-chairing the manufacturing committee of the USIBC, which promotes specific areas to progress Prime Minister Modi’s Make it in India initiatives. Past USIBC Global Leadership Award honorees include: Jeff Bezos, founder and CEO of Amazon; Dilip Shanghvi, founder and managing director of Sun Pharmaceuticals; Indra Nooyi, chairman and CEO of PepsiCo; and Shobhana Bhartia, chairperson and editorial director of the Hindustan Times Group. Dow (NYSE: DOW) combines the power of science and technology to passionately innovate what is essential to human progress. The Company is driving innovations that extract value from material, polymer, chemical and biological science to help address many of the world's most challenging problems, such as the need for fresh food, safer and more sustainable transportation, clean water, energy efficiency, more durable infrastructure, and increasing agricultural productivity. Dow's integrated, market-driven portfolio delivers a broad range of technology-based products and solutions to customers in 175 countries and in high-growth sectors such as packaging, infrastructure, transportation, consumer care, electronics, and agriculture. In 2016, Dow had annual sales of $48 billion and employed approximately 56,000 people worldwide. The Company's more than 7,000 product families are manufactured at 189 sites in 34 countries across the globe. References to "Dow" or the "Company" mean The Dow Chemical Company and its consolidated subsidiaries unless otherwise expressly noted. More information about Dow can be found at www.dow.com. ®TM Trademark of The Dow Chemical Company (“Dow”) or an affiliated company of Dow


Sarasota, FL, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled “Generic Drug Market by Brand (Pure Generic and Branded Generic) for Central Nervous System (CNS), Cardiovascular, Dermatology, Oncology, Respiratory and Others Therapeutic Applications - Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 – 2021”. According to the report, the global generic drug market accounted for around USD 200.20 billion in 2015 and is expected to reach approximately USD 380.60 billion by 2021, growing at a CAGR of around 10.8 % between 2016 and 2021. Pharmacology is the study of drugs and medicines, including their uses, effects, and characteristic. Generic drugs are chemically identical to their branded counterparts. Although generic drugs are bioequivalent to branded drugs, they are sold at the significant discount from branded drugs prices. As per the FDA approval, the generic drug should contain the same active ingredient as their branded counterpart; it should be bioequivalent and should meet batch requirements for identity, quality, purity, and strength. It should be identical on the route of administration and dosage form. It should be manufactured under the same rules and regulation of FDA’s good manufacturing practice required for branded drugs. Generic drugs manufacturing companies are capable of selling generic drugs at the lower price because they are not required to repeat costly clinical trials and pay for marketing and promotion strategies. Browse through 13 Market Tables and 24 Figures spread through 110 Pages and in-depth TOC on "Global Generic Drug Market: By Brands, Application, Size, Share, Trends, Manufacturers, Segment and Forecast 2015-2021”. Globally, the market for the generic drug has been propelled by new government initiatives to produce generic drugs and mainly to promote the use of generic drugs against chronic diseases. Patent expiration of branded drugs is one of the key influencers for the growth and prime reason for generating more revenue for generic drugs market. Moreover, new emerging markets of developing countries and low cost of generic drugs are majorly responsible for thickening the growth of generic drugs market. In spite of this, the market is affected by high competition within the globe and it is due to, economic expenditure required for the production of generic drugs is the very low thus a number of leading companies taking interest in the production of generic drugs.  In future, new developing and uncovered markets may responsible for the generation of new opportunities. The market for the generic drug has been segmented on the basis of the brand as pure generic drug and branded generic drugs. Branded generic drugs are marketed under another company’s brand name but they are bioequivalent to their generic counterparts. Due to high involvement of companies in manufacturing pure generic drugs, pure generic drug segment is dominating the market. Browse the full "Generic Drug Market by Brand (Pure Generic and Branded Generic) for Central Nervous System (CNS), Cardiovascular, Dermatology, Oncology, Respiratory and others Therapeutic Applications - Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2015 – 2021" report at https://www.zionmarketresearch.com/report/generic-drug-market Based on the therapeutic application the market of generic drugs has been segmented as central nervous system (CNS), cardiovascular, dermatology, oncology, respiratory and others. With more than 20% revenue contribution, the cardiovascular segment was leading the generic drug market in 2015 due to a number of patent expiry of cardiovascular drugs. With more than 15 % revenue contribution, central nervous system (CNS) will show significant growth over the forecast period. The market for the generic drug has been segmented into North America, Europe, Asia-Pacific, Latin America and the Middle East & Africa. North America is dominating the generic drug market due to high demand and increasing the prevalence of chronic diseases. Asia-Pacific is expected to show good growth in the forecast period. In Asia Pacific, India and China are leading countries in the genetic drug market. Key operating players for the generic drugs market are Teva Pharmaceutical Industries Ltd., Novartis International AG, Mylan N.V., Abbott Healthcare Pvt. Ltd., Actavis Pharmaceuticals and Sun Pharmaceuticals. This report segments the generic drugs market as follows: Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.


Patent
China Fuel Huaibei Bioenergy Technology Development Co. and Sun Pharmaceuticals Inc. | Date: 2013-01-30

The invention provides a continuous reaction system, and more particularly relates to a continuous reaction system comprising subcritical and/or supercritical liquid as solvent and a reactant as solid. The invention can prevent cavitation in the reaction system effectively, and realize maximum conversion of the solid reactant material.


Patent
China Fuel Huaibei Bioenergy Technology Development Co. and Sun Pharmaceuticals Inc. | Date: 2011-05-18

The invention provides a process for direct liquification of cellulosic biomass, which may be used to liquefy all of the organics in cellulosic biomass, including all high molecular polymeric components such as carbohydrates and lignins, into small molecular organics in a short time under mild conditions. In other words, there is provided a technology capable of converting cellulosic biomass into oil. The resultant renewable high-quality oil may be converted into liquid fuels such as gasoline etc., or used as starting materials in chemical engineering industry. The technology for direct liquification of cellulosic biomass as disclosed in the invention is the first one-step process in the world for direct liquification of cellulosic biomass without black tar formation and gasification.


Patent
China Fuel Huaibei Bioenergy Technology Development Co. and Sun Pharmaceuticals Inc. | Date: 2013-01-30

A method of refining cellulosic biomass, comprising synchronous hydrolyzation of at least 85wt% organic polymers , based on the total weight of the cellulosic biomass, in the cellulosic biomass into small molecular organic compounds. The synchronous hydrolyzation is catalytic hydrolyzation for which the catalyst used is a substance represented by L-M-S - H or L-M = S, wherein M represents metal, carbon or silicon, S represents a heteroatom, L represents one or more ligands, and H represents hydrogen.


Patent
Sun Pharmaceuticals Ltd. | Date: 2014-02-04

The present invention provides a sterile solution comprising leuprolide acetate in a pharmaceutically acceptable vehicle, wherein solution is present as a reservoir in a multiple dose pen injection device, the device being adapted to subcutaneously inject a portion of the said reservoir in a single daily dose and further being adapted to provide multiple portions of solution said while the reservoir remains sterile.

Loading Sun Pharmaceuticals Inc. collaborators
Loading Sun Pharmaceuticals Inc. collaborators